VBL Therapeutics

Company Overview

Snapshot

Founded in January 2000 by Dror Harats, VBL Therapeutics operated with 11–50 employees. The company raised a total of $109.77 million across 5 funding rounds from 8 investors. In February 2023, VBL Therapeutics was acquired by Notable Labs.

Business overview

VBL Therapeutics is a biopharmaceutical company focused on developing targeted therapies for immune-inflammatory diseases. The company's core technology centers on its Monocyte Targeting Technology (MTT), which aims to limit chronic inflammation by targeting a novel protein called MOSPD2, or the "mono-walk" receptor, selectively expressed on monocytes. Its lead MTT candidate, VB-601, is an investigational monoclonal antibody designed to block monocytes from reaching inflamed tissues. VBL Therapeutics serves the pharmaceutical and life sciences sectors, with potential applications across a range of immune-inflammatory conditions including multiple sclerosis, rheumatoid arthritis, and non-alcoholic steatohepatitis (NASH).

Strategic signal

In February 2023, VBL Therapeutics announced a definitive merger agreement with Notable Labs, signaling a strategic shift for the company. This acquisition indicates a consolidation within the biopharmaceutical sector, where VBL's therapeutic pipeline and technology will likely be integrated into Notable Labs' operations, potentially accelerating the development and commercialization of its targeted therapies for immune-inflammatory diseases.

Company Intelligence Q&A

What was a significant corporate event for VBL Therapeutics in early 2023?

In February 2023, VBL Therapeutics announced a definitive merger agreement with Notable Labs, leading to its acquisition.

What was the outcome of VBL Therapeutics' Phase 3 OVAL trial in July 2022?

In July 2022, VBL Therapeutics announced top-line data from its Phase 3 OVAL trial of Ofra-Vec in patients with platinum-resistant ovarian cancer, which did not meet its primary endpoint.

What strategic action did VBL Therapeutics take in August 2022?

In August 2022, VBL Therapeutics announced a workforce reduction and initiated a corporate process to explore strategic options following the results of its OVAL trial.

What was a key development for VBL Therapeutics' VB-601 program in September 2020?

In September 2020, VBL Therapeutics successfully completed a Pre-IND meeting with the FDA regarding the proposed clinical development of VB-601, its lead.

What patent milestone did VBL Therapeutics achieve in October 2020?

In October 2020, VBL Therapeutics announced an additional new European patent in its MOSPD2 platform technology for the treatment of cancer, further protecting its anti-MOSPD2 antibodies for inflammation until at least July 2036.